Lidocaine for status epilepticus in adults

Seizure

Volumn 31, Issue , 2015, Pages 41-48

  Zeiler, F A ^a   Zeiler, K J ^a,c   Kazina, C J ^a   Teitelbaum, J ^b   Gillman, L M ^a,d   West, M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c 3801 Rue University ^*  (Canada)

^d ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

Adult; Lidocaine; Refractory; Status epilepticus

Indexed keywords

LIDOCAINE; PHENYTOIN; ANTICONVULSIVE AGENT;

ADULT DISEASE; CARDIOPULMONARY INSUFFICIENCY; EPILEPTIC STATE; HEART ARREST; HUMAN; HYPOTENSION; INFUSION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; PATHOPHYSIOLOGY; SEIZURES; STATUS EPILEPTICUS;

ADULT; ANTICONVULSANTS; HUMANS; LIDOCAINE; SEIZURES; STATUS EPILEPTICUS;

EID: 84941052933     PISSN: 10591311     EISSN: 15322688     Source Type: Journal    
DOI: 10.1016/j.seizure.2015.07.003     Document Type: Review

References (38)

1. G.M. Brophy, R. Bell, J. Claassen, B. Alldredge, T.P. Bleck, T. Glauser, and et al. Guidelines for the evaluation and management of status epilepticus Neurocrit Care 17 2012 3 23
2. J. Claassan, R. Silbergleit, S.D. Weingart, and W.D. Smith Emergency neurological life support Neurocrit Care 17 2012 S73 S78
3. G.K. Motamedi, R.P. Lesser, and S. Vicini Therapeutic brain hypothermia, its mechanisms of action and its prospects as a treatment for epilepsy Epilepsia 54 6 2013 959 970
4. M.J. Hilz, J. Bauer, D. Claus, H. Stefan, and B. Neundorfer Isoflurane anesthesia in the treatment of nonconvulsive status epilepticus J Neurol 239 1992 135 137
5. W.A. Kofke, R.S.K. Young, P. Davis, S.K. Woelfel, L. Gray, D. Johnson, and et al. Isoflurane for refractory status epilepticus: a clinical series Anesthesiology 71 1989 653 659
6. V. De Herdt, L. Waterschoot, K. Vonck, B. Dermaut, H. Verhelst, R. Van Coster, and et al. Vagus nerve stimulation for refractory status epilepticus J Pediatr Neurol 13 3 2009 286 289
7. D.J. Donahue, L. Bailey, A. Hernandez, S. Malik, J. Honeycutt, and M.S. Perry Vagus nerve stimulation as treatment for refractory status epilepticus Epilepsy Curr 13 2013 226
8. V. Lambrecq, F. Villéga, C. Marchal, V. Michel, D. Guehl, J.Y. Rotge, and et al. Refractory status epilepticus: electroconvulsive therapy as a possible therapeutic strategy Seizure 21 9 2012 661 664
9. J.J Riviello Jr., J. Claassen, S.M. LaRoche, M.R. Sperling, B. Alldredge, T.P. Bleck, and et al. Treatment of status epilepticus: an international survey of experts Neurocrit Care 18 2 2013 193 200
10. K. Mori, H. Ito, Y. Toda, T. Hashimoto, M. Miyazaki, T. Saijo, and et al. Successful management of intractable epilepsy with lidocaine tapes and continuous subcutaneous lidocaine infusion Epilepsia 45 10 2004 1287 1290
11. M. Lundqvist, J. Agren, L. Hellstrom-Westas, R. Flink, and R. Wickstrom Efficacy and safety for lidocaine treatment of neonatal seizures Acta Pediatr 102 2013 863 867
12. S. Hamano, N. Sugiyama, S. Yamashita, M. Tanaka, M. Hayakawa, and M. Minamitani Intravenous lidocaine for status epilepticus during childhood Dev Med Child Neurol 48 3 2006 220 222
13. Y.C. Yang, C.S. Huang, and C.C. Kuo Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na channels Anesthesiology 113 1 2010 160 174
14. P. Aggarwal, and J.P. Wali Lidocaine in refractory status epilepticus: a forgotten drug in the emergency department Am J Emerg Med 11 3 1993 243 244
15. C.G. Bernhard, E. Bohm, and S. Hojeberg A new treatment for status epilepticus AMA Arch Neurol Psychiatry 74 2 1955 208 214
16. M.C. Cervenka, A.L. Hartman, A. Venkatesan, R.G. Geocadin, and E.H. Kossoff The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit Neurocrit Care 15 3 2011 519 524
17. C.M. De Giorgio, K. Altman, E. Hamilton-Byrd, and A.L. Rabinowicz Lidocaine in refractory status epilepticus: confirmation of efficacy with continuous EEG monitory Epilepsia 33 5 1992 913 916
18. L.J. Lemmen, M. Klassen, and B. Duiser Intravenous lidocaine in the treatment of convulsions JAMA 239 19 1978 2025
19. Moddel G, Schabitz WR, Dziewas R, Bosebeck F, Kellinghaus C, Anneken K, et al. Lidocaine as a treatment option for refractory status epilepticus. Epilepsia 200; 48(Suppl. 3):44-5.
20. H.H. Morris Lidocaine: a neglected anticonvulsant? South Med J 72 12 1979 1564 1566
21. A. Nandakumar, J. Andrzejowski, and D. Turnbull Case report: New Onset Drug Resistant Status Epilepticus (NODRSE) J Neurosurg Anesthesiol 20 3 2008 218
22. J. Pascual, J. Ciudad, and J. Berciano Role of lidocaine (lignocaine) in managing status epilepticus J Neurol Neurosurg Psych 55 1992 49 51
23. J. Pascual, M.J. Sedano, J.M. Polo, and J. Berciano Intravenous lidocaine for status epilepticus Epilepsia 29 5 1988 584 589
24. D. Taverner, and W.A. Bain Intravenous lidocaine as an anticonvulsant in status epilepticus and serial epilepsy Lancet 2 7057 1958 1145 1147
25. J.L. Fernandez-Torre, P.W. Kaplan, M. Rebollo, A. Gutierrez, M.A. Hernandez-Hernandez, and J.L. Vazquez-Higuera Ambulatory non-convulsive status epilepticus evolving into a malignant form Epileptic Disord 14 1 2012 41 50
26. G. Westreich, and A.W. Kneller Intravenous lidocaine for status epilepticus Minn Med 55 9 1972 807 808
27. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, Version 5.1.0. http://handbook.cochrane.org [accessed 25.10.13].
28. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and P. Group Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement Ann Intern Med 151 4 2009 264 269
29. Phillips B, Ball C, Sackett D, Straus S, Haynes B, Dawes M. Oxford Centre for Evidence-Based Medicine Levels of Evidence. Version 2009. http://www.cebm.net/?o=1025 [accessed October 2013].
30. G.H. Guyatt, A.D. Oxman, G. Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello, and et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
31. G.H. Guyatt, A.D. Oxman, R. Kunz, G.E. Vist, Y. Falck-Ytter, H.J. Schünemann, and et al. Rating quality of evidence and strength of recommendations: what is quality of evidence and why is it important to clinicians? BMJ 336 7651 2008 995 998
32. H.J. Schünemann, A.D. Oxman, J. Brozek, P. Glasziou, R. Jaeschke, G.E. Vist, and et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies BMJ 336 7653 2008 1106 1110
33. G.H. Guyatt, A.D. Oxman, R. Kunz, R. Jaeschke, M. Helfand, A. Liberati, and et al. Rating quality of evidence and strength of recommendations: incorporating considerations of resources use into grading recommendations BMJ 336 7654 2008 1170 1173
34. G.H. Guyatt, A.D. Oxman, R. Kunz, Y. Falck-Ytter, G.E. Vist, A. Liberati, and et al. Rating quality of evidence and strength of recommendations: going from evidence to recommendations BMJ 336 7652 2008 1049 1051
35. R. Jaeschke, G.H. Guyatt, P. Dellinger, H. Schünemann, M.M. Levy, R. Kunz, and et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive BMJ 337 2008 a744
36. C.-C. Kuo A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na channels Mol Pharmacol 54 1998 712 721
37. C.-C. Kuo, B.-S. Lou, and R.-C. Huang Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels Mol Pharmacol 57 2000 135 143
38. S. Shorvon, and M. Ferlisi The outcome of therapies in refractory and super-refractory status convulsive epilepticus and recommendations for therapy Brain 135 2012 2314 2328